Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
cytokine induced killer cells (1 trial)
ibritumomab tiuxetan (Zevalin) (1 trial)
Lymphoma (Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Neoplasms (Phase 2)
Trials (2 total)
Trial APIs (2 total)